Seeking Alpha

Sangamo selloff weighs on gene therapy developers

|About: Editas Medicine, Inc. (EDIT)|By: , SA News Editor

The tepid ZFN data-stoked selloff in Sangamo Therapeutics is weighing on other gene therapy players. CRISPR/Cas9 gene editors Editas Medicine (EDIT -8.3%), CRISPR Therapeutics (CRSP -9%) and Intellia Therapeutics (NTLA -7.6%) appear to be under the most pressure.

Selected tickers: (AXON -11.7%)(AVRO -6%)(MGTX -1.3%)(BLUE -3.9%)(GNPX -6.5%)(FIXX -2.6%)(XON -5.7%)(FCSC +1.6%)(RCKT -3.1%)(ABEO -9.7%)(CAPR -2.2%)(NITE +2.5%)(SRPT -3.2%)(ZIOP -5.2%)(FLXN -4.6%)(RGNX -2.4%)(BMRN -2.6%)(BOLD -4.6%)(RARE -4.3%)(QURE -1.5%)(VYGR -2.9%)(BNTC -0.7%)(KRYS +3.7%)(ONCE -3.5%)(ADVM -2.7%)